Inhibrx, Inc. Common Stock
INBX
INBX was delisted on the 29th of May, 2024.
111 hedge funds and large institutions have $716M invested in Inhibrx, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 42 increasing their positions, 36 reducing their positions, and 9 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
53% more call options, than puts
Call options by funds: $55K | Put options by funds: $36K
44% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 9
17% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 36
4% more funds holding
Funds holding: 107 → 111 (+4)
23% less capital invested
Capital invested by funds: $935M → $716M (-$219M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$36.6M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$18.2M |
| 3 |
PA
Perceptive Advisors
New York
|
+$13.2M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
+$10.7M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$9.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$11.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.29M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$5.34M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.32M |
| 5 |
State Street
Boston,
Massachusetts
|
-$4.2M |
INBX Hedge Fund Activity: Q3 2023 in Review
111 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Inhibrx, Inc. Common Stock (INBX) for Q3 2023, worth a combined $716M — down 23% from $935M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new INBX positions and 9 closed out — a net gain of 4 holders — while 42 added to existing stakes and 36 trimmed.
The largest buyer was TCG Crossover Management, opening a new position worth an estimated $36.6M. The largest seller was Capital Research Global Investors, cutting an estimated $11.1M.
- 111 institutional investors held Inhibrx, Inc. Common Stock (INBX) as of Q3 2023, up from 107 in Q2 2023.
- Funds reported $716M of Inhibrx, Inc. Common Stock stock for Q3 2023, down 23% quarter-over-quarter.
- 13 funds opened new Inhibrx, Inc. Common Stock positions in Q3 2023 and 9 closed out, a net change of +4 holders.
- The largest Inhibrx, Inc. Common Stock buyer in Q3 2023 was TCG Crossover Management, an estimated $36.6M added.
- The largest Inhibrx, Inc. Common Stock seller in Q3 2023 was Capital Research Global Investors, an estimated $11.1M sold.
Based on aggregated 13F filings for Q3 2023.